Cell Surface Proteome의 Label-free 정량화를 위한 "Cell Surface Capture" 워크플로우

Executive Industry Relevance

Comprehensive cell surface proteome profiling is critical for target validation and therapeutic hypothesis generation in oncology and immunotherapy pipelines. The described workflow enables label-free quantification and enrichment of membrane proteins, directly supporting the identification of disease-specific antigens and actionable targets. This capability enhances predictive confidence at the early discovery and lead identification stages, informing portfolio triage and risk-adjusted advancement.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables systematic identification of cell-type and disease-specific surface antigens for target nomination.
• Supports biological de-risking by distinguishing tumor-associated proteins from normal cell surface markers.
• Facilitates functional target validation through quantitative proteomic outputs.
• Improves predictive confidence for downstream immunotherapy and antibody development.

Screening & Assay Development

• Provides enriched, validated protein samples for robust assay development and screening workflows.
• Delivers quantitative, reproducible data suitable for standardization across discovery teams.
• Enables scalable profiling of multiple cell types or conditions for comparative analysis.
• Supports reliable evaluation of candidate molecules targeting surface proteins.

Translational & Preclinical Research

• Aligns surfaceome profiling with disease-relevant models to inform translational biomarker strategies.
• Ensures continuity from discovery through preclinical validation by enabling targeted follow-up (e.g., flow cytometry, targeted proteomics).
• Reduces mechanistic ambiguity in target selection for preclinical studies.

Pipeline & Workflow Integration

This workflow integrates at the interface of early discovery and lead identification, providing a bridge to preclinical validation for surface protein targets.

• Discovery Biology: Supports hypothesis testing and pathway clarification by mapping the surfaceome landscape.
• Screening: Delivers reproducible, quantitative protein enrichment for assay readiness and cross-sample comparison.
• Analytics: Generates robust mass spectrometry data and statistical outputs (e.g., Andromeda scores, sample-to-sample correlation) for confident decision-making.
• Translational Research: Enables targeted validation of candidate antigens in disease-relevant systems.
• Enterprise Reuse: Establishes a reusable platform for surfaceome profiling across diverse cell types and disease models.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target selection.
• Operational Value: Standardizes enrichment and quantification workflows for reproducibility and scalability.
• Strategic Value: Informs go/no-go decisions and enhances capital efficiency by focusing on validated surface targets.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of immunotherapy and antibody programs.

Implementation Considerations

• Requires expertise in proteomics, mass spectrometry, and sample preparation optimization.
• Demands access to advanced analytical instrumentation and data processing software (e.g., MaxQuant).
• Necessitates cross-team standardization for sample input and workflow reproducibility.
• Adaptable to various cell types but may require iterative optimization for each context.
• Dependent on robust validation strategies (e.g., targeted flow cytometry) for downstream confirmation.

Biopharma FAQs